Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8945820 | 0.79 | HTT (0.39) | GRIA2GRIA4POLBMAPTKMT2A | |
| SCHEMBL11561052 | 0.76 | SMN1; SMN2 (0.35) | POLBALDH1A1HPGDKDM4E | |
| SCHEMBL6833252 | 0.75 | RECQL (0.33) | POLBMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL8996614 | 0.70 | — | — | |
| SCHEMBL11563374 | 0.70 | — | — | |
| SCHEMBL5156393 | 0.69 | — | — | |
| SCHEMBL8945779 | 0.68 | CDK1 (0.32) | POLBMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL11450579 | 0.67 | MEN1 (0.33) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL21917573 | 0.67 | HTT (0.42) | POLBMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL9664186 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6247947-A | — | — | None | — | — | JP | disclosed |
| US-6989451-B2 | Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) | VALEANT RESEARCH & DEVELOPMENT (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040039037-A1 | Heterocyclic compounds and uses thereof | VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA (PL) | 2004-02-26 | — | — | US | disclosed |
| US-5484934-A | FUNGICIDE, WOOD PRESERVATIVE | NIHON NOHYAKU CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| JP-H06247947-A | ISOTHIAZOLE DERIVATIVE, ITS PRODUCTION AND USE THEREOF | NIPPON NOHYAKU CO LTD | 1994-09-06 | — | — | JP | disclosed |
| EP-0604978-A1 | Isothiazole derivatives, a process for production thereof and uses thereof | NIHON NOHYAKU CO., LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0578246-A1 | Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient | NIHON NOHYAKU CO., LTD. (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-4167575-A | BIOCIDES | ROHM AND HAAS COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| US-4053479-A | BIOCIDES | ROHM AND HAAS COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3957808-A | BIOCIDES | ROHM AND HAAS COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039037-A1 | Heterocyclic compounds and uses thereof | MAP3K1, MAP3K20, MAP4K2 | GRIA2 3149/4885GRIA4 3538/4885POLB 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.